LASSBio-1135 is primarily investigated for its potential anti-inflammatory and analgesic properties. It acts as a modulator of intracellular signaling pathways involved in pain and inflammation, particularly through the enhancement of cyclic AMP (cAMP) levels by inhibiting phosphodiesterase enzymes. This mechanism makes it a candidate for the development of treatments for chronic inflammatory conditions and neuropathic pain. Research also suggests it may have beneficial effects in models of visceral pain and gastrointestinal motility disorders, indicating possible application in conditions like irritable bowel syndrome (IBS). Due to its ability to target specific pathways with reduced side effects compared to conventional NSAIDs, LASSBio-1135 is considered a lead compound in the design of new safer analgesic and anti-inflammatory drugs.